SHANGHAI and HONG KONG, August 18, 2026

Antengene Corporation Limited, a commercial-stage global biotechnology company focused on innovative therapies for autoimmune diseases, solid tumors and hematological malignancies, presented key research and development updates at the Evercore 2nd China Biotech Summit. The company highlighted updated clinical data for ATG-022, a CLDN18.2 antibody-drug conjugate (ADC), while also introducing its TriGager™ T-cell engager (TCE) platform and ATG-207, an αCD3-TGF-β bifunctional fusion protein. The updates underscore Antengene’s continued efforts to develop differentiated therapeutic platforms across oncology and autoimmune diseases.

ATG-022 Shows Encouraging Phase II Clinical Data

Antengene presented updated results from the Phase II CLINCH study evaluating ATG-022 in patients with moderate to high CLDN18.2 expression. As of June 26, 2026, patients receiving the 2.4 mg/kg dose achieved an objective response rate (ORR) of 42.4% and a disease control rate (DCR) of 90.9%, with median overall survival (mOS) of 12.85 months. In the 1.8 mg/kg cohort, the ORR was 46.7%, while the DCR reached 86.7%; median overall survival had not yet been reached after a median follow-up of 14.03 months. One patient in each dose cohort achieved a complete response. The company also reported a favorable safety profile in the 1.8 mg/kg cohort. The incidence of Grade ≥3 treatment-related adverse events increased slightly to 21.0% from 19.4% at the previous data cutoff, while 9.7% of patients experienced dose reductions because of treatment-related adverse events. Antengene said the stability of severe treatment-related adverse events after extended follow-up supports continued investigation of ATG-022 in combination with chemotherapy and anti-PD-1 antibodies.

TCE Platforms Expand Antengene’s Technology Toolbox

Antengene also showcased its proprietary AnTenGager® and TriGager™ TCE platforms, highlighting the company’s strategy of developing flexible molecular engineering technologies for different therapeutic targets. AnTenGager is described as a second-generation TCE platform featuring “2+1” bivalent binding, steric-hindrance masking and proprietary CD3 sequences with fast on/off kinetics. These design elements are intended to support efficacy while potentially reducing the risk of cytokine release syndrome (CRS). The platform has generated multiple development programs targeting autoimmune diseases, solid tumors and hematological malignancies. The newly presented TriGager™ platform is a trispecific TCE technology that supports molecular designs incorporating AND-Gate, True AND-Gate and OR-Gate logic. AND-Gate configurations require co-expression of two disease-associated antigens before T-cell-mediated killing is triggered, while OR-Gate configurations can respond to either of two target antigens. Antengene said these approaches are intended to improve target specificity, address heterogeneous antigen expression and potentially reduce off-target toxicity.

Advertisement

cGxPJobs Banner

ATG-207 Adds Autoimmune Development Opportunity

Antengene also introduced ATG-207, described as a first-in-class αCD3-TGF-β bifunctional fusion protein being developed for T-cell-mediated autoimmune diseases. The company previously disclosed preclinical data for the candidate at the 2026 European Congress of Rheumatology. The program adds another therapeutic modality to Antengene’s broader pipeline, complementing its oncology-focused ADC and TCE programs. The company currently has multiple investigational programs spanning preclinical, clinical and commercial stages, with ATG-022 among its key clinical assets. Antengene has obtained 33 IND approvals across the United States and Asia and NDA approvals in 10 Asia-Pacific markets, according to the company. Its lead commercial product, XPOVIO® (selinexor), is approved across multiple Asia-Pacific markets.

Source: Antengene press relese